0001209191-20-043313.txt : 20200722
0001209191-20-043313.hdr.sgml : 20200722
20200722164738
ACCESSION NUMBER: 0001209191-20-043313
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200720
FILED AS OF DATE: 20200722
DATE AS OF CHANGE: 20200722
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EHRLICH JASON
CENTRAL INDEX KEY: 0001754049
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38682
FILM NUMBER: 201041923
MAIL ADDRESS:
STREET 1: 2631 HANOVER STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kodiak Sciences Inc.
CENTRAL INDEX KEY: 0001468748
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270476525
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2631 HANOVER STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94304
BUSINESS PHONE: 650-281-0850
MAIL ADDRESS:
STREET 1: 2631 HANOVER STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94304
FORMER COMPANY:
FORMER CONFORMED NAME: Oligasis, LLC
DATE OF NAME CHANGE: 20090721
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-20
0
0001468748
Kodiak Sciences Inc.
KOD
0001754049
EHRLICH JASON
2631 HANOVER STREET
PALO ALTO
CA
94304
0
1
0
0
See Remarks
Common Stock
2020-07-20
4
M
0
6950
10.29
A
40934
D
Common Stock
2020-07-20
4
S
0
1474
49.767
D
39460
D
Common Stock
2020-07-20
4
S
0
5100
50.573
D
34360
D
Common Stock
2020-07-20
4
S
0
376
51.19
D
33984
D
Stock Option (Right to Buy)
10.29
2020-07-20
4
M
0
6950
0.00
D
2028-08-29
Common Stock
6950
386475
D
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $49.01 to $49.95, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $50.16 to $50.90, inclusive.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $51.18 to $51.21, inclusive.
Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.
Chief Medical Officer and Chief Development Officer
/s/ Carlton Fleming, Attorney-in-Fact for Jason Ehrlich
2020-07-22